Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Tecvayli — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Gilead Sciences logo
GILDTecartus — Total revenues
$75M-3.8%
Biogen logo
BIIBTecfidera — Revenue
$2.48B+1.9%
Biogen logo
BIIBTECFIDERA — Total Revenue
$109.5M-46.9%
Cumberland Pharmaceuticals logo
CPIXTalicia — Revenue
$1.92M—
Gilead Sciences logo
GILDTrodelvy — Total revenues
$402M+37.2%
Biogen logo
BIIBTYSABRI — Total Revenue
$441.5M+15.7%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's tecvayli — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's tecvayli — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported tecvayli — sales to customers (note 9) of $202M in Q1 2026.
How has Johnson & Johnson's tecvayli — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's tecvayli — sales to customers (note 9) increased by 33.8% year-over-year, from $151M to $202M.
What is the long-term trend for Johnson & Johnson's tecvayli — sales to customers (note 9)?
Over 3 years (2022 to 2025), Johnson & Johnson's tecvayli — sales to customers (note 9) has grown at a 254.8% compound annual growth rate (CAGR), from $15M to $670M.
What does tecvayli — sales to customers (note 9) mean?
This metric represents the total revenue generated from the sale of the specific pharmaceutical product Tecvayli to external customers. It serves as a key indicator of the product's market adoption, commercial success, and contribution to the company's overall oncology portfolio revenue. Tracking this figure allows investors to assess the growth trajectory and competitive positioning of this specific therapeutic asset within the broader biopharmaceutical market.